1 / 15

Peptic Ulcer Drugs Market Analysis| Coherent Market Insights

Proton Pump Inhibitors segment in the global peptic ulcer drugs market is expected to reach at CAGR of 2.8% during the forecast period.

shrutiCMI
Download Presentation

Peptic Ulcer Drugs Market Analysis| Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. PEPTIC ULCER DRUGS MARKET ANALYSIS Peptic Ulcer Drugs Market,ByProduct Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonists, Antibiotics, Ulcer Protective), By Disease Indication (Gastritis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD)), By Distribution Channel (Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce), By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

  3. The global peptic ulcer drugs market is estimated to account for US$ 45,951.2 Mn in terms of value by the end of 2027. Drivers • Increasing prevalence of peptic ulcers is a major factor boosting growth of the global peptic ulcer drugs market over the forecast period. For instance, according to the study, ‘A36 The Global Incidence of Peptic Ulcer Disease and Its Complications at The Turn Of The 21st Century: A Systematic Review’, published in the Journal of the Canadian Association of Gastroenterology in March 2018, Spain recorded the highest annual incidence of all PUD (complicated and uncomplicated) with 141.8 cases per 100,000 persons.

  4. Moreover, change in lifestyle such as stress, diet, and high rate of smoking is also expected to propel growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018. • North America region held dominant position in the global peptic ulcer drugs market in 2018, accounting for 41.4% share in terms of volume, followed by Europe.

  5. Figure 1.Global Peptic Ulcer Drugs Market Value (US$ Mn),by Region,2018

  6. Market Restraints • Prolonged use of peptic ulcer drugs such as proton pump inhibitors and antibiotics may lead to increased risk of hip bone fracture as the ability to absorb calcium and iron decreases. Other side effects include, risk of opportunistic infections with S. pneumonia and C. defficile, owing to diminished natural gut flora. Such scenario is expected to hamper growth of the global peptic ulcer drugs market. • Moreover, wide availability of generic drugs and poor patient compliance to medication in some countries is also expected to hamper growth of the market.

  7. Market Opportunities • Key players in the market can focus on personalized treatment and management of patients suffering from PUD in order to enhance their market share. For instance, in July 2019, in a study published in the Journal of Clinical Medicine (MDPI), researchers from Institute of Medical Microbiology, Switzerland, concluded that next generation sequencing technology may facilitate rapid monitoring of virulence determinants in H. pylori, which may prove beneficial in personalized treatment and management of patients suffering from PUD. • Moreover, high doses of nonsteroidal anti-inflammatory drug (NSAIDs) is associated with risk of recurrent PUD. Therefore, market players may focus on R&D in H. pylori eradication therapy as it has the potential to reduce the risk of recurrent PUD among NSAID users.

  8. Proton Pump Inhibitors segment in the global peptic ulcer drugs market was valued at US$ 24,799.4 Mn in 2018 and is expected to reach US$ 31,895.7 Mn by 2027 at a CAGR of 2.8% during the forecast period.

  9. Market Trends • The use of AI in diagnosis of peptic ulcers is a major trend in the global peptic ulcer drugs market. For instance, in December 2019, Inspirata, a US-based cancer informatics and digital pathology provider, partnered with DeePathology on Artificial Intelligence (AI)-based Helicobacter Pylori (H Pylori) pathology testing. • Key players in the market are focused on assessing the efficacy of potassium-competitive acid blocker in combination therapy for the treatment of PUD. For instance, in December 2019, Phathom Pharmaceuticals initiated pivotal phase III trial that is expected to assess the efficacy of Vonoprazan in combination with Amoxicillin against Vonoprazan in combination with Amoxicillin and Clarithromycin for the successful eradication of H. pylori infection.

  10. Competitive Section Major players operating in the global peptic ulcer drugs market include, Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Abbott Laboratories, AstraZeneca plc., RedHillBiopharma, Cadila Healthcare Ltd., NovitiumPharma LLC, BoehringerIngelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline plc.

  11. Key Developments • Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in November 2019, RedHillBiopharma received the U.S. FDA approval for Talicia, a treatment for Helicobacter pylori (H. pylori) infection in adults, regardless of ulcer status. • In October 2019, NovitiumPharma LLC recalled ranitidine hydrochloride capsules (indicated for the treatment of duodenal ulcer) in the U.S., owing to potential N-Nitrosodimethylamine (NDMA) (a probable human carcinogen) amounts above levels established by the U.S. FDA.

  12. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference: https://www.coherentmarketinsights.com/market-insight/peptic-ulcer-drugs-market-3246

  13. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  14. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  15. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related